+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Magnetic Resonance Imaging (MRI) Contrast Agents Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update

  • PDF Icon

    Report

  • 168 Pages
  • October 2024
  • Region: Global
  • GlobalData
  • ID: 6018446
The Medical Devices sector report, “Magnetic Resonance Imaging (MRI) Contrast Agents Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update" provides comprehensive information about the Magnetic Resonance Imaging (MRI) Contrast Agents pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

Magnetic Resonance Imaging (MRI) utilizes radiofrequency and a strong magnetic field to generate clear and detailed images of internal organs and tissues. MRI is generally preferred for the diagnosis of brain and other neurological disorders.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Magnetic Resonance Imaging (MRI) Contrast Agents under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Magnetic Resonance Imaging (MRI) Contrast Agents and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to Buy

The report enables you to:

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
  • Identify and understand important and diverse types of Magnetic Resonance Imaging (MRI) Contrast Agents under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date

Table of Contents

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Magnetic Resonance Imaging (MRI) Contrast Agents Overview
3 Products under Development
3.1 Magnetic Resonance Imaging (MRI) Contrast Agents - Pipeline Products by Stage of Development
3.2 Magnetic Resonance Imaging (MRI) Contrast Agents - Pipeline Products by Segment
3.3 Magnetic Resonance Imaging (MRI) Contrast Agents - Pipeline Products by Territory
3.4 Magnetic Resonance Imaging (MRI) Contrast Agents - Pipeline Products by Regulatory Path
3.5 Magnetic Resonance Imaging (MRI) Contrast Agents - Pipeline Products by Estimated Approval Date
3.6 Magnetic Resonance Imaging (MRI) Contrast Agents - Ongoing Clinical Trials
4 Magnetic Resonance Imaging (MRI) Contrast Agents - Pipeline Products under Development by Companies
4.1 Magnetic Resonance Imaging (MRI) Contrast Agents Companies - Pipeline Products by Stage of Development
4.2 Magnetic Resonance Imaging (MRI) Contrast Agents - Pipeline Products by Stage of Development
5 Magnetic Resonance Imaging (MRI) Contrast Agents Companies and Product Overview6 Magnetic Resonance Imaging (MRI) Contrast Agents- Recent Developments
7 Appendix
7.1 Methodology
7.2 About the Analyst
7.3 Contact the Publisher
7.4 Disclaimer
List of Tables
  • Magnetic Resonance Imaging (MRI) Contrast Agents - Pipeline Products by Stage of Development
  • Magnetic Resonance Imaging (MRI) Contrast Agents - Pipeline Products by Segment
  • Magnetic Resonance Imaging (MRI) Contrast Agents - Pipeline Products by Territory
  • Magnetic Resonance Imaging (MRI) Contrast Agents - Pipeline Products by Regulatory Path
  • Magnetic Resonance Imaging (MRI) Contrast Agents - Pipeline Products by Estimated Approval Date
  • Magnetic Resonance Imaging (MRI) Contrast Agents - Ongoing Clinical Trials
  • Magnetic Resonance Imaging (MRI) Contrast Agents Companies - Pipeline Products by Stage of Development
  • Magnetic Resonance Imaging (MRI) Contrast Agents - Pipeline Products by Stage of Development
  • 5M Biomed LLC Pipeline Products & Ongoing Clinical Trials Overview
  • Surface Functionalized Magnetic Iron Oxide Nanorods - Product Status
  • Surface Functionalized Magnetic Iron Oxide Nanorods - Product Description
  • Water Soluble Magnetic Iron Oxide Nanocubes - Product Status
  • Water Soluble Magnetic Iron Oxide Nanocubes - Product Description
  • Adamas Nanotechnologies Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Photo-Hyperpolarizable Nanodiamond-Based 13C Contrast Agent - Product Status
  • Photo-Hyperpolarizable Nanodiamond-Based 13C Contrast Agent - Product Description
  • Alzeca Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview
  • ADx Nanoparticle - Product Status
  • ADx Nanoparticle - Product Description
  • Alzeca Biosciences Inc - Ongoing Clinical Trials Overview
  • ADx Nanoparticle - A Phase 1, Controlled, Open-label, Single Dose, Dose-escalation, Clinical Proof-of-concept Study of MRI Enhanced With ADx-001 (DSPE-DOTA-Gd Liposomal Injection) in Patients with Brain Amyloid Deposits as Demonstrated by Amyloid PET
  • Antaros Medical AB Pipeline Products & Ongoing Clinical Trials Overview
  • Gadoxetate DCE-MR Imaging Agent - Liver Toxicity - Product Status
  • Gadoxetate DCE-MR Imaging Agent - Liver Toxicity - Product Description
  • Ascelia Pharma AB Pipeline Products & Ongoing Clinical Trials Overview
  • Orviglance - Product Status
  • Orviglance - Product Description
  • Second Generation Mangoral - Product Status
  • Second Generation Mangoral - Product Description
  • Ascelia Pharma AB - Ongoing Clinical Trials Overview
  • Orviglance - Study Evaluate the Influence of Hepatic Impairment on the Safety, Pharmacokinetics and Pharmacodynamics of Mangoral
  • B-Aegis Life Sciences & Research Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • OncoSense - Product Status
  • OncoSense - Product Description
  • Bayer AG Pipeline Products & Ongoing Clinical Trials Overview
  • Gadoquatrane Contrast Agent - Product Status
  • Gadoquatrane Contrast Agent - Product Description
  • Next Generation Liver MRI Contrast Agent - Product Status
  • Next Generation Liver MRI Contrast Agent - Product Description
  • BBS NanoTechnology Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • FCA1 - Gd Containing Paramagnetic MR T1 Contrast Agent - Product Status
  • FCA1 - Gd Containing Paramagnetic MR T1 Contrast Agent - Product Description
  • Brown University Pipeline Products & Ongoing Clinical Trials Overview
  • MR Imaging Probe - Cancer - Product Status
  • MR Imaging Probe - Cancer - Product Description
  • Case Western Reserve University Pipeline Products & Ongoing Clinical Trials Overview
  • AI Contrast Agent - Product Status
  • AI Contrast Agent - Product Description
  • ZD2-Gd3N@C80 - Product Status
  • ZD2-Gd3N@C80 - Product Description
  • EOS Biosciences Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
  • Eos-002 - Product Status
  • Eos-002 - Product Description
  • Eos-004 - Product Status
  • Eos-004 - Product Description
  • Ferric Contrast Inc Pipeline Products & Ongoing Clinical Trials Overview
  • K720 - Kidney Tumors - Product Status
  • K720 - Kidney Tumors - Product Description
  • L410 - Liver Tumor - Product Status
  • L410 - Liver Tumor - Product Description
  • MP89 - Multipurpose - Product Status
  • MP89 - Multipurpose - Product Description
  • GE HealthCare Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Manganese-Based Macrocyclic Magnetic Resonance Imaging (MRI) Contrast Agent - Product Status
  • Manganese-Based Macrocyclic Magnetic Resonance Imaging (MRI) Contrast Agent - Product Description
  • GE HealthCare Technologies Inc - Ongoing Clinical Trials Overview
  • Manganese-Based Macrocyclic Magnetic Resonance Imaging (MRI) Contrast Agent - A Phase I Study to Assess the Safety Profile of Injectable Manganese Contrast Agent
  • Georgia State University Pipeline Products & Ongoing Clinical Trials Overview
  • Protein Contrast Agent - Product Status
  • Protein Contrast Agent - Product Description
  • Hana Pharm Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • HNP-2006 - Product Status
  • HNP-2006 - Product Description
  • Harvard University Pipeline Products & Ongoing Clinical Trials Overview
  • Hyperpolarized MRI Contrast Agent - Product Status
  • Hyperpolarized MRI Contrast Agent - Product Description
  • Hugo W. Moser Research Institute at Kennedy Krieger Inc Pipeline Products & Ongoing Clinical Trials Overview
  • D-Glucose Contrast Agent - Product Status
  • D-Glucose Contrast Agent - Product Description
  • IC Targets AS Pipeline Products & Ongoing Clinical Trials Overview
  • Mangafodipir - Product Status
  • Mangafodipir - Product Description
  • IC Targets AS - Ongoing Clinical Trials Overview
  • Mangafodipir - Investigation of Blood-brain-barrier Breakdown Using Manganese Magnetic Resonance Imaging in Drug-resistant Epilepsy
  • Imagion Biosystems Inc Pipeline Products & Ongoing Clinical Trials Overview
  • MagSense HER2+ Breast Cancer Imaging Agent - Product Status
  • MagSense HER2+ Breast Cancer Imaging Agent - Product Description
  • Magsense Prostate Cancer Imaging Agent - Product Status
  • Magsense Prostate Cancer Imaging Agent - Product Description
  • iMax Diagnostic Imaging Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • Gadopentetate Dimeglumine - Product Status
  • Gadopentetate Dimeglumine - Product Description
  • Macrocyclic MRI Contrast Agent - Product Status
  • Macrocyclic MRI Contrast Agent - Product Description
  • Indian Institute of Technology Delhi Pipeline Products & Ongoing Clinical Trials Overview
  • MRI Imaging Iron Nano-Particles - Product Status
  • MRI Imaging Iron Nano-Particles - Product Description
  • Inlighta Biosciences LLC Pipeline Products & Ongoing Clinical Trials Overview
  • Novel Contrast Agent - Lung Fibrosis - Product Status
  • Novel Contrast Agent - Lung Fibrosis - Product Description
  • ProCA32.Collagen - Product Status
  • ProCA32.Collagen - Product Description
  • ProCA32.collagen+ - Product Status
  • ProCA32.collagen+ - Product Description
  • ProCA32.CXCR4 - Product Status
  • ProCA32.CXCR4 - Product Description
  • ProCA32.EGFR - Product Status
  • ProCA32.EGFR - Product Description
  • ProCA32.GRPR - Product Status
  • ProCA32.GRPR - Product Description
  • ProCA32.HER2 - Product Status
  • ProCA32.HER2 - Product Description
  • ProCA32.Integrin - Product Status
  • ProCA32.Integrin - Product Description
  • ProCA32.PD-L1 - Product Status
  • ProCA32.PD-L1 - Product Description
  • ProCA32.PSMA - Product Status
  • ProCA32.PSMA - Product Description
  • ProCA32.vEGFR - Product Status
  • ProCA32.vEGFR - Product Description
  • Inventera Pharmaceutical Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • INV-001 - Product Status
  • INV-001 - Product Description
  • INV-002 - Product Status
  • INV-002 - Product Description
  • INV-003 - Product Status
  • INV-003 - Product Description
  • Iowa State University Pipeline Products & Ongoing Clinical Trials Overview
  • Gd5Si4 MRI Contrast Agent - Product Status
  • Gd5Si4 MRI Contrast Agent - Product Description
  • King's College London Pipeline Products & Ongoing Clinical Trials Overview
  • Magnetic Resonance Contrast Agent - Product Status
  • Magnetic Resonance Contrast Agent - Product Description
  • Knowledgepie Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • Gd-Based Contrast Agent - Product Status
  • Gd-Based Contrast Agent - Product Description
  • LadeRx LLC Pipeline Products & Ongoing Clinical Trials Overview
  • Chelated Manganese-Based Contrast Agent - Product Status
  • Chelated Manganese-Based Contrast Agent - Product Description
  • Lantheus Medical Imaging Inc Pipeline Products & Ongoing Clinical Trials Overview
  • LMI 1174 - Product Status
  • LMI 1174 - Product Description
  • Lipella Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview
  • LP - 20 - Product Status
  • LP - 20 - Product Description
  • Lipella Pharmaceuticals Inc - Ongoing Clinical Trials Overview
  • LP - 20 - Human Clinical Study of a Novel Bladder MRI Contrast Agent
  • Massachusetts General Hospital Pipeline Products & Ongoing Clinical Trials Overview
  • Mn-PyC3A - Product Status
  • Mn-PyC3A - Product Description
  • MRI Contrast Agent - Product Status
  • MRI Contrast Agent - Product Description
  • Massachusetts Institute of Technology Pipeline Products & Ongoing Clinical Trials Overview
  • Metal-Free MRI Contrast Agent - Product Status
  • Metal-Free MRI Contrast Agent - Product Description
  • MRI-Based Calcium Sensor - Product Status
  • MRI-Based Calcium Sensor - Product Description
  • Molecular Theranostics LLC Pipeline Products & Ongoing Clinical Trials Overview
  • MRI Contrast Agent - Prostate Cancer (MT218) - Product Status
  • MRI Contrast Agent - Prostate Cancer (MT218) - Product Description
  • Molecular Theranostics LLC - Ongoing Clinical Trials Overview
  • MRI Contrast Agent - Prostate Cancer (MT218) - An Open-label Evaluation of a Targeted Magnetic Resonance Imaging Contrast Agent (MT218) in Prostate Cancer Patients
  • Nanosion Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • Polymeric Gd Agent - Product Status
  • Polymeric Gd Agent - Product Description
  • National University of Singapore Pipeline Products & Ongoing Clinical Trials Overview
  • Dual-Mode Contrast Agent - Product Status
  • Dual-Mode Contrast Agent - Product Description
  • Northwestern University Pipeline Products & Ongoing Clinical Trials Overview
  • Gd(III) Contrast Agent - Product Status
  • Gd(III) Contrast Agent - Product Description
  • Peptide Amphiphile-Conjugated MRI Contrast Agent - Product Status
  • Peptide Amphiphile-Conjugated MRI Contrast Agent - Product Description
  • Polarean Imaging PLC Pipeline Products & Ongoing Clinical Trials Overview
  • HP 3He - Product Status
  • HP 3He - Product Description
  • XENOVIEW (xenon Xe 129 hyperpolarized) - Pediatrics - Product Status
  • XENOVIEW (xenon Xe 129 hyperpolarized) - Pediatrics - Product Description
  • QurCan Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Manganescan (T-MX) - Product Status
  • Manganescan (T-MX) - Product Description
  • Reveal Pharmaceutical Inc Pipeline Products & Ongoing Clinical Trials Overview
  • RVP-001 - Product Status
  • RVP-001 - Product Description
  • SG Endocrine Research LLC Pipeline Products & Ongoing Clinical Trials Overview
  • MRI Imaging Agent - Product Status
  • MRI Imaging Agent - Product Description
  • Signablok Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Gadolinium-Based Contrast Agents - Product Status
  • Gadolinium-Based Contrast Agents - Product Description
  • Southern Illinois University Carbondale Pipeline Products & Ongoing Clinical Trials Overview
  • Metabolic MRI Contrast Agent - Product Status
  • Metabolic MRI Contrast Agent - Product Description
  • SPION Based Imaging Agents - Product Status
  • SPION Based Imaging Agents - Product Description
  • SPAGO Nanomedical AB Pipeline Products & Ongoing Clinical Trials Overview
  • SN132D - Product Status
  • SN132D - Product Description
  • Sree Chitra Tirunal Institute for Medical Sciences & Technology Pipeline Products & Ongoing Clinical Trials Overview
  • Negative MR Contrast Agents - Product Status
  • Negative MR Contrast Agents - Product Description
  • Positive MR Contrast Agent - Product Status
  • Positive MR Contrast Agent - Product Description
  • SunTech Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
  • STD-002 - Product Status
  • STD-002 - Product Description
  • The Chinese University of Hong Kong Pipeline Products & Ongoing Clinical Trials Overview
  • Nanoparticle Contrast Agent - Product Status
  • Nanoparticle Contrast Agent - Product Description
  • Theragnostic Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Mangradex - Product Status
  • Mangradex - Product Description
  • University College London Pipeline Products & Ongoing Clinical Trials Overview
  • LipoGlucoCEST - Product Status
  • LipoGlucoCEST - Product Description
  • University of Arizona Pipeline Products & Ongoing Clinical Trials Overview
  • Molecular Scaffold - Contrast Agent - Product Status
  • Molecular Scaffold - Contrast Agent - Product Description
  • University of Bordeaux Pipeline Products & Ongoing Clinical Trials Overview
  • Antibody Based Imaging Agent - Product Status
  • Antibody Based Imaging Agent - Product Description
  • University of Chicago Pipeline Products & Ongoing Clinical Trials Overview
  • MRI Imaging Agent - Ovarian Cancer - Product Status
  • MRI Imaging Agent - Ovarian Cancer - Product Description
  • University of Gottingen Pipeline Products & Ongoing Clinical Trials Overview
  • Iron paraCEST MRI Contrast Agent - Product Status
  • Iron paraCEST MRI Contrast Agent - Product Description
  • University of Louisville Pipeline Products & Ongoing Clinical Trials Overview
  • Voltage-Sensitive MRI Myelographic Contrast Agents - Product Status
  • Voltage-Sensitive MRI Myelographic Contrast Agents - Product Description
  • University of Oxford Pipeline Products & Ongoing Clinical Trials Overview
  • Biodegradable MRI Imaging Agent - Product Status
  • Biodegradable MRI Imaging Agent - Product Description
  • Targeted Image Contrast Agent - Product Status
  • Targeted Image Contrast Agent - Product Description
  • University of Pennsylvania Pipeline Products & Ongoing Clinical Trials Overview
  • Gadolinium Labeled Nanocluster - Product Status
  • Gadolinium Labeled Nanocluster - Product Description
  • Hyper-CEST MR Contrast Agent - Product Status
  • Hyper-CEST MR Contrast Agent - Product Description
  • University of Toronto Pipeline Products & Ongoing Clinical Trials Overview
  • MnTCP Imaging Agent - Product Status
  • MnTCP Imaging Agent - Product Description
  • MnTPPS3 Imaging Agent - Product Status
  • MnTPPS3 Imaging Agent - Product Description
  • Videns og Forskningscenter for Alternativ Behandling Pipeline Products & Ongoing Clinical Trials Overview
  • VLS-1 - Product Status
  • VLS-1 - Product Description
  • VLS-4 - Product Status
  • VLS-4 - Product Description
  • Voyageur Pharmaceuticals Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • VY-101 - Product Status
  • VY-101 - Product Description
  • Washington University in St Louis Pipeline Products & Ongoing Clinical Trials Overview
  • Colloidal Iron Oxide Contrast Agent - Product Status
  • Colloidal Iron Oxide Contrast Agent - Product Description
  • Wayne State University Pipeline Products & Ongoing Clinical Trials Overview
  • Next Generation MRI Contrast Imaging Agent - Product Status
  • Next Generation MRI Contrast Imaging Agent - Product Description
  • Weizmann Institute of Science Pipeline Products & Ongoing Clinical Trials Overview
  • Novel MRI Contrast Agent - Product Status
  • Novel MRI Contrast Agent - Product Description
  • Xemed LLC Pipeline Products & Ongoing Clinical Trials Overview
  • MagniXene - Product Status
  • MagniXene - Product Description
  • Xemed LLC - Ongoing Clinical Trials Overview
  • MagniXene - A Prospective Study of Hyperpolarized 129 Xe MRI in in a Pediatric Population with Bronchopulmonary Dysplasia
  • MagniXene - Functional and Structural Assessment of Endobronchial Valve Recipients Using Dynamic Hyperpolarized Xenon-129 MRI
  • MagniXene - Hyperpolarized 129 Xenon MRI in a Pediatric Population with Lung Transplant
  • MagniXene - New Strategies for Pulmonary Assessment in Spinal and Chest Wall Deformity
  • MagniXene - Pilot Study of Hyperpolarized Xenon Functional Lung Imaging in COPD Patients Undergoing Targeted Lung Denervation
  • Glossary
List of Figures
  • Magnetic Resonance Imaging (MRI) Contrast Agents - Pipeline Products by Stage of Development
  • Magnetic Resonance Imaging (MRI) Contrast Agents - Pipeline Products by Segment
  • Magnetic Resonance Imaging (MRI) Contrast Agents - Pipeline Products by Territory
  • Magnetic Resonance Imaging (MRI) Contrast Agents - Pipeline Products by Regulatory Path
  • Magnetic Resonance Imaging (MRI) Contrast Agents - Pipeline Products by Estimated Approval Date
  • Magnetic Resonance Imaging (MRI) Contrast Agents - Ongoing Clinical Trials

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • 5M Biomed LLC
  • Adamas Nanotechnologies Inc
  • Alzeca Biosciences Inc
  • Antaros Medical AB
  • Ascelia Pharma AB
  • B-Aegis Life Sciences & Research Pvt Ltd
  • Bayer AG
  • BBS NanoTechnology Ltd
  • Brown University
  • Case Western Reserve University
  • EOS Biosciences Inc (Inactive)
  • Ferric Contrast Inc
  • GE HealthCare Technologies Inc
  • Georgia State University
  • Hana Pharm Co Ltd
  • Harvard University
  • Hugo W. Moser Research Institute at Kennedy Krieger Inc
  • IC Targets AS
  • Imagion Biosystems Inc
  • iMax Diagnostic Imaging Ltd
  • Indian Institute of Technology Delhi
  • Inlighta Biosciences LLC
  • Inventera Pharmaceutical Co Ltd
  • Iowa State University
  • King's College London
  • Knowledgepie Pvt Ltd
  • LadeRx LLC
  • Lantheus Medical Imaging Inc
  • Lipella Pharmaceuticals Inc
  • Massachusetts General Hospital
  • Massachusetts Institute of Technology
  • Molecular Theranostics LLC
  • Nanosion Co Ltd
  • National University of Singapore
  • Northwestern University
  • Polarean Imaging PLC
  • QurCan Therapeutics Inc
  • Reveal Pharmaceutical Inc
  • SG Endocrine Research LLC
  • Signablok Inc
  • Southern Illinois University Carbondale
  • SPAGO Nanomedical AB
  • Sree Chitra Tirunal Institute for Medical Sciences & Technology
  • SunTech Medical Inc
  • The Chinese University of Hong Kong
  • Theragnostic Technologies Inc
  • University College London
  • University of Arizona
  • University of Bordeaux
  • University of Chicago
  • University of Gottingen
  • University of Louisville
  • University of Oxford
  • University of Pennsylvania
  • University of Toronto
  • Videns og Forskningscenter for Alternativ Behandling
  • Voyageur Pharmaceuticals Ltd
  • Washington University in St Louis
  • Wayne State University
  • Weizmann Institute of Science
  • Xemed LLC